Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;276(4):1135-1146.
doi: 10.1007/s00405-019-05282-2. Epub 2019 Jan 16.

Contemporary treatment patterns and outcomes of salivary gland carcinoma: a National Cancer Database review

Jay K Ferrell  1 , Jess C Mace  2 , Daniel Clayburgh  2
Affiliations

Contemporary treatment patterns and outcomes of salivary gland carcinoma: a National Cancer Database review

Jay K Ferrell et al. Eur Arch Otorhinolaryngol. 2019 Apr.

Abstract

Purpose: Salivary gland carcinomas (SGC) are rare malignancies and data regarding treatment outcomes stratified by histologic subtype are currently limited. This study aims to examine current, national treatment patterns and overall survival (OS) of patients with the major histologic subtypes of salivary gland carcinoma.

Subjects and methods: A review was performed of the National Cancer Database (NCDB) of patients with confirmed diagnoses of mucoepidermoid carcinoma, acinic cell carcinoma, adenoid cystic carcinoma, adenocarcinoma, or carcinoma ex pleomorphic receiving curative treatment between 2004 and 2014. Univariate and multivariate regression modeling were performed to identify risk factors significantly associated with overall survival (OS). Adjusted survival analyses stratified by treatment and staging were performed with the primary outcome of overall survival (OS) and were further stratified based on histologic subtype.

Results: The final analysis included 7342 patients [3547 men (48.3%) and 3795 women (51.7%); mean age 58.3 years (range 18-90 years)]. Mucoepidermoid carcinoma was the most common histology encountered [n = 2669 (36.4%)]. Unadjusted and adjusted analysis demonstrated improved survival with surgery and radiation therapy (RT) for adenoid cystic (HR = 0.69; p = 0.029), adenocarcinoma (HR = 0.61; p < 0.001), high-grade mucoepidermoid carcinoma (HR = 0.70; p = 0.026), and carcinoma ex pleomorphic (HR = 0.64; p = 0.028), while surgery with chemoradiation therapy (CRT) was associated with worse OS regardless of histologic subtype. The impact of advanced stage on survival varied amongst the histologic subtypes but portended the worst prognosis for patients with adenocarcinoma and carcinoma ex pleomorphic.

Conclusions: The results of this NCDB review demonstrate unique treatment patterns and survival outcomes for SGC based on major histologic subtype.

Keywords: Cancer of salivary gland; Head and neck cancer; National Cancer Database; Salivary gland; Treatment outcomes.

PubMed Disclaimer

References

    1. Boukheris H, Curtis RE, Land CE, Dores GM (2009) Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. Cancer Epidemiol Biomarkers Prev 18:2899–2906. https://doi.org/10.1158/1055-9965.EPI-09-0638 - DOI - PubMed - PMC
    1. Spitz MR, Fueger JJ, Goepfert H, Newell GR (1990) Salivary gland cancer: a case-control investigation of risk factors. Arch Otolaryngol Head Neck Surg 116:1163–1166. https://doi.org/10.1001/archotol.1990.01870100057012 - DOI - PubMed
    1. Pan SY, De Groh M, Morrison H (2017) A case-control study of risk factors for salivary gland cancer in Canada. J cancer epidemiol. https://doi.org/10.1155/2017/4909214 - DOI - PubMed - PMC
    1. Adelstein DJ, Koyfman SA, El-Naggar AK, Hanna EY (2012) Biology and management of salivary gland cancers. Semin Radiat Oncol 22:245–253. https://doi.org/10.1016/j.semradonc.2012.03.009 - DOI - PubMed
    1. Schoenfeld JD, Sher DJ, Norris CM, Haddad RI, Posner MR, Balboni TA et al (2012) Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys 82:308–314. https://doi.org/10.1016/j.ijrobp.2010.09.042 - DOI - PubMed

MeSH terms

LinkOut - more resources